150 related articles for article (PubMed ID: 21029363)
1. Recombinant human tissue factor pathway inhibitor exerts anticoagulant, anti-inflammatory and antimicrobial effects in murine pneumococcal pneumonia.
Van Den Boogaard FE; Brands X; Schultz MJ; Levi M; Roelofs JJ; Van 't Veer C; Van Der Poll T
J Thromb Haemost; 2011 Jan; 9(1):122-32. PubMed ID: 21029363
[TBL] [Abstract][Full Text] [Related]
2. Endogenous tissue factor pathway inhibitor has a limited effect on host defence in murine pneumococcal pneumonia.
van den Boogaard FE; van 't Veer C; Roelofs JJ; Meijers JC; Schultz MJ; Broze GJ; van der Poll T
Thromb Haemost; 2015 Jul; 114(1):115-22. PubMed ID: 25832548
[TBL] [Abstract][Full Text] [Related]
3. Feasibility and Safety of Local Treatment with Recombinant Human Tissue Factor Pathway Inhibitor in a Rat Model of Streptococcus pneumoniae Pneumonia.
van den Boogaard FE; Hofstra JJ; van 't Veer C; Levi MM; Roelofs JJ; van der Poll T; Schultz MJ
PLoS One; 2015; 10(5):e0127261. PubMed ID: 25992779
[TBL] [Abstract][Full Text] [Related]
4. Nebulized Recombinant Human Tissue Factor Pathway Inhibitor Attenuates Coagulation and Exerts Modest Anti-inflammatory Effects in Rat Models of Lung Injury.
van den Boogaard FE; Hofstra JJ; Brands X; Levi MM; Roelofs JJ; Zaat SA; Van't Veer C; van der Poll T; Schultz MJ
J Aerosol Med Pulm Drug Deliv; 2017 Apr; 30(2):91-99. PubMed ID: 27977318
[TBL] [Abstract][Full Text] [Related]
5. Tissue factor pathway inhibitor and bacterial infection.
Maroney SA; Mast AE
J Thromb Haemost; 2011 Jan; 9(1):119-21. PubMed ID: 21210950
[TBL] [Abstract][Full Text] [Related]
6. Recombinant activated protein C attenuates coagulopathy and inflammation when administered early in murine pneumococcal pneumonia.
Schouten M; van 't Veer C; Roelofs JJ; Gerlitz B; Grinnell BW; Levi M; van der Poll T
Thromb Haemost; 2011 Dec; 106(6):1189-96. PubMed ID: 21901240
[TBL] [Abstract][Full Text] [Related]
7. Local activation of the tissue factor-factor VIIa pathway in patients with pneumonia and the effect of inhibition of this pathway in murine pneumococcal pneumonia.
Rijneveld AW; Weijer S; Bresser P; Florquin S; Vlasuk GP; Rote WE; Spek CA; Reitsma PH; van der Zee JS; Levi M; van der Poll T
Crit Care Med; 2006 Jun; 34(6):1725-30. PubMed ID: 16625114
[TBL] [Abstract][Full Text] [Related]
8. Plasma-derived human antithrombin attenuates ventilator-induced coagulopathy but not inflammation in a Streptococcus pneumoniae pneumonia model in rats.
Aslami H; Haitsma JJ; Hofstra JJ; Florquin S; Dos Santos C; Streutker C; Zhang H; Levi M; Slutsky AS; Schultz MJ
J Thromb Haemost; 2012 Mar; 10(3):399-410. PubMed ID: 22236057
[TBL] [Abstract][Full Text] [Related]
9. Levofloxacin-ceftriaxone combination attenuates lung inflammation in a mouse model of bacteremic pneumonia caused by multidrug-resistant Streptococcus pneumoniae via inhibition of cytolytic activities of pneumolysin and autolysin.
Majhi A; Adhikary R; Bhattacharyya A; Mahanti S; Bishayi B
Antimicrob Agents Chemother; 2014 Sep; 58(9):5164-80. PubMed ID: 24957840
[TBL] [Abstract][Full Text] [Related]
10. Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
Henken S; Bohling J; Martens-Lobenhoffer J; Paton JC; Ogunniyi AD; Briles DE; Salisbury VC; Wedekind D; Bode-Böger SM; Welsh T; Bange FC; Welte T; Maus UA
Antimicrob Agents Chemother; 2010 Feb; 54(2):707-17. PubMed ID: 19917756
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of β-Lactam-plus-Macrolide Combination Therapy in a Mouse Model of Lethal Pneumococcal Pneumonia.
Yoshioka D; Kajiwara C; Ishii Y; Umeki K; Hiramatsu K; Kadota J; Tateda K
Antimicrob Agents Chemother; 2016 Oct; 60(10):6146-54. PubMed ID: 27480866
[TBL] [Abstract][Full Text] [Related]
12. Protease activated receptor 4 limits bacterial growth and lung pathology during late stage Streptococcus pneumoniae induced pneumonia in mice.
de Stoppelaar SF; Van't Veer C; van den Boogaard FE; Nieuwland R; Hoogendijk AJ; de Boer OJ; Roelofs JJ; van der Poll T
Thromb Haemost; 2013 Sep; 110(3):582-92. PubMed ID: 23783078
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic recombinant murine activated protein C attenuates pulmonary coagulopathy and improves survival in murine pneumococcal pneumonia.
Schouten M; van 't Veer C; van den Boogaard FE; Gerlitz B; Grinnell BW; Roelofs JJ; Levi M; van der Poll T
J Infect Dis; 2010 Nov; 202(10):1600-7. PubMed ID: 20925531
[TBL] [Abstract][Full Text] [Related]
14. The endothelial protein C receptor impairs the antibacterial response in murine pneumococcal pneumonia and sepsis.
Schouten M; de Boer JD; Kager LM; Roelofs JJ; Meijers JC; Esmon CT; Levi M; van 't Veer C; van der Poll T
Thromb Haemost; 2014 May; 111(5):970-80. PubMed ID: 24401906
[TBL] [Abstract][Full Text] [Related]
15. Nebulized antithrombin limits bacterial outgrowth and lung injury in Streptococcus pneumoniae pneumonia in rats.
Hofstra JJ; Cornet AD; de Rooy BF; Vlaar AP; van der Poll T; Levi M; Zaat SA; Schultz MJ
Crit Care; 2009; 13(5):R145. PubMed ID: 19740417
[TBL] [Abstract][Full Text] [Related]
16. The cytoprotective effects of endogenous activated protein C reduce activation of coagulation during murine pneumococcal pneumonia and sepsis.
Schouten M; van 't Veer C; Poulussen N; Meijers JC; Levi M; Esmon CT; van der Poll T
Thromb Res; 2015 Mar; 135(3):537-43. PubMed ID: 25586194
[TBL] [Abstract][Full Text] [Related]
17. Btk inhibitor ibrutinib reduces inflammatory myeloid cell responses in the lung during murine pneumococcal pneumonia.
de Porto AP; Liu Z; de Beer R; Florquin S; de Boer OJ; Hendriks RW; van der Poll T; de Vos AF
Mol Med; 2019 Jan; 25(1):3. PubMed ID: 30646846
[TBL] [Abstract][Full Text] [Related]
18. Ceftriaxone pharmacokinetics in interleukin-10-treated murine pneumococcal pneumonia.
Wang E; Bergeron Y; Bergeron MG
J Antimicrob Chemother; 2005 May; 55(5):721-6. PubMed ID: 15772139
[TBL] [Abstract][Full Text] [Related]
19. Antithrombin inhibits bronchoalveolar activation of coagulation and limits lung injury during Streptococcus pneumoniae pneumonia in rats.
Choi G; Hofstra JJ; Roelofs JJ; Rijneveld AW; Bresser P; van der Zee JS; Florquin S; van der Poll T; Levi M; Schultz MJ
Crit Care Med; 2008 Jan; 36(1):204-10. PubMed ID: 18090375
[TBL] [Abstract][Full Text] [Related]
20. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia.
de Jonge E; Dekkers PE; Creasey AA; Hack CE; Paulson SK; Karim A; Kesecioglu J; Levi M; van Deventer SJ; van Der Poll T
Blood; 2000 Feb; 95(4):1124-9. PubMed ID: 10666180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
